HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The von Hippel-Lindau gene, kidney cancer, and oxygen sensing.

Abstract
Recent studies of a relatively rare hereditary cancer syndrome, von Hippel-Lindau (VHL) disease, have shed new light on the molecular pathogenesis of kidney cancer and, perhaps more important, on how mammalian cells sense and respond to changes in oxygen availability. This knowledge is already translating into new therapeutic targets for kidney cancer as well as for multiple conditions, such as myocardial infarction and stroke, in which ischemia plays a pathogenic role. This review summarizes the current knowledge of the molecular pathogenesis of von Hippel-Lindau disease and the role of the VHL gene product (pVHL) in kidney cancer and the mammalian oxygen sensing pathway.
AuthorsWilliam G Kaelin Jr
JournalJournal of the American Society of Nephrology : JASN (J Am Soc Nephrol) Vol. 14 Issue 11 Pg. 2703-11 (Nov 2003) ISSN: 1046-6673 [Print] United States
PMID14569079 (Publication Type: Journal Article, Review)
Chemical References
  • Tumor Suppressor Proteins
  • Ubiquitin-Protein Ligases
  • Von Hippel-Lindau Tumor Suppressor Protein
  • VHL protein, human
Topics
  • Animals
  • Cell Hypoxia (physiology)
  • Humans
  • Kidney Neoplasms (etiology, metabolism, pathology)
  • Signal Transduction
  • Tumor Suppressor Proteins (metabolism)
  • Ubiquitin-Protein Ligases (metabolism)
  • Von Hippel-Lindau Tumor Suppressor Protein
  • von Hippel-Lindau Disease (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: